Virtua Clinical Trials

SWOG S2013

S2013, “Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study” (NCT# 04871542)

The purpose of this study is to try to learn how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient will develop mild or serious side effects from the medication.
Patients will get the same standard treatment for their type of cancer that they would get if they were not in this study. In addition to the standard treatment, they will fill out forms several times that ask questions about their personal health and medical history, medications, physical and emotional wellbeing before and during treatment, and if they develop a severe side effect from the treatment. In the future, this information could predict who is likely to have serious side effects and help participants and their doctors make better decisions about cancer treatments.

Click Here for more information

Principle Investigator: James Lee, M.D.

Clinical Trials for Solid Tumors